Latest Conference Articles

December 12th 2022, 5:25pm

ASH Annual Meeting and Exposition

Tisagenlecleucel produced durable responses in patients with relapsed/refractory follicular lymphoma, including those with high-risk disease characteristics.

December 12th 2022, 12:29pm

ASH Annual Meeting and Exposition

Second-line treatment with lisocabtagene maraleucel (liso-cel; Breyanzi) reduced the risk of an event occurring by 64.4% compared with standard-of-care chemoimmunotherapy induction and autologous stem cell transplantation for patients with high-risk relapsed/refractory large B-cell lymphoma.

December 12th 2022, 12:04am

ASH Annual Meeting and Exposition

Ajay Chari, MD, discusses findings from the phase 1/2 MonumenTAL-1 trial investigating talquetamab in heavily pretreated patients with relapsed/refractory multiple myeloma.

December 11th 2022, 11:56pm

ASH Annual Meeting and Exposition

Jesus G. Berdeja, MD, discusses the investigation of BMS-986393 in patients with relapsed/refractory multiple myeloma.

December 11th 2022, 11:37pm

ASH Annual Meeting and Exposition

Patients receiving axicabtagene ciloleucel reported a temporary reduction in quality of life, followed by statistically significant improvements in overall QOL and symptoms within the first year of treatment for relapsed/refractory large B-cell lymphoma.

December 11th 2022, 11:12pm

ASH Annual Meeting and Exposition

The addition of ibrutinib to standard chemoimmunotherapy induction followed by autologous stem cell transplantation (ASCT) and 2 years of maintenance ibrutinib significantly improved outcomes vs standard chemoimmunotherapy induction and ASCT alone for younger patients with mantle cell lymphoma.

December 11th 2022, 11:08pm

ASH Annual Meeting and Exposition

The combination of selinexor and ruxolitinib significantly reduced spleen volume and total symptom score while achieving hemoglobin stabilization in an open-label dose-escalation/dose-expansion, phase 1 study of patients with treatment-naïve myelofibrosis.

December 11th 2022, 10:39pm

ASH Annual Meeting and Exposition

Daratumumab in addition to bortezomib, lenalidomide, and dexamethasone induction/consolidation therapy, as well as with lenalidomide maintenance, showcased a promising health-related quality of life benefit for patients with transplant eligible, newly diagnosed multiple myeloma.

December 11th 2022, 10:04pm

ASH Annual Meeting and Exposition

Mezigdomide showed notable clinical activity and a manageable safety profile when combined with dexamethasone in patients with triple-class relapsed or refractory multiple myeloma.

December 11th 2022, 9:29pm

ASH Annual Meeting and Exposition

The combination of zilovertamab and ibrutinib resulted in promising clinical response and progression-free survival rates and showcased a tolerable toxicity profile in patients with mantle cell lymphoma and chronic lymphocytic leukemia.

December 11th 2022, 9:05pm

ASH Annual Meeting and Exposition

The CD19-targeted CAR T-cell therapy rapcabtagene autoleucel was found to be well tolerated and to yield durable responses in patients with relapsed/refractory diffuse large B-cell lymphoma who had undergone 2 or more prior lines of therapy.

December 11th 2022, 8:20pm

ASH Annual Meeting and Exposition

The addition of magrolimab to azacitidine and venetoclax produced high complete response rates and was well tolerated as first-line therapy in patients with high-risk de novo and secondary acute myeloid leukemia regardless of TP53 mutation status.

December 11th 2022, 7:25pm

ASH Annual Meeting and Exposition

Crovalimab led to rapid and stable hemolysis control and transfusion avoidance, with no new safety signals, in Chinese patients with paroxysmal nocturnal hemoglobinuria.

December 11th 2022, 6:08pm

ASH Annual Meeting and Exposition

Iberdomide monotherapy or in combination with anti-CD20 antibodies was well tolerated and found to elicit encouraging responses in patients with relapsed or refractory lymphoma.

December 11th 2022, 4:58pm

ASH Annual Meeting and Exposition

The combination of ibrutinib and venetoclax produced rapid and deep responses in previously untreated patients with Waldenström macroglobulinemia but there was a higher-than-anticipated rate of ventricular arrhythmia that prompted stopping treatment.

December 11th 2022, 1:00am

ASH Annual Meeting and Exposition

Zanubrutinib sustained high response rates and led to durable disease control with low incidence of hypertension and atrial fibrillation in patients with relapsed/refractory marginal zone lymphoma, according to findings from the final analysis of the phase 2 MAGNOLIA trial.

December 11th 2022, 12:58am

ASH Annual Meeting and Exposition

Ziftomenib monotherapy had a manageable toxicity profile and provided pronounced antileukemic activity when given at a 600-mg dose in heavily pretreated patients with relapsed or refractory acute myeloid leukemia.

December 11th 2022, 12:45am

OncLive News Network: On Location at ASH 2022

OncLive® will be LIVE with OncLive® News Network: On Location at the 2022 ASH Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across hematologic oncology during the conference.

December 11th 2022, 12:30am

ASH Annual Meeting and Exposition

Tycel Phillips, MD, MPH, discusses the investigation of glofitamab monotherapy in relapsed/refractory mantle cell lymphoma.

December 11th 2022, 12:26am

ASH Annual Meeting and Exposition

Mazyar Shadman, MD, MPH, discusses the examination of zanubrutinib in patients with B-cell malignancies who were intolerant to acalabrutinib.